---
title: "Purple Biotech Ltd (PPBT.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PPBT.US.md"
symbol: "PPBT.US"
name: "Purple Biotech Ltd"
industry: "Pharmaceuticals"
datetime: "2026-05-20T05:55:33.656Z"
locales:
  - [en](https://longbridge.com/en/quote/PPBT.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PPBT.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PPBT.US.md)
---

# Purple Biotech Ltd (PPBT.US)

## Company Overview

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [urple-biotech.com](https://urple-biotech.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.20 | 114 | - | - | - |
| PB | 3.26 | 122 | 1.17 | 0.21 | 0.17 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 3.51 |
| Highest Target | 30.00 |
| Lowest Target | 30.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/PPBT.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/PPBT.US/norm.md)
- [Related News](https://longbridge.com/en/quote/PPBT.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/PPBT.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**